The cost and quality of life impact of glaucoma in Tanzania: An observational study

To determine the cost and quality of life impact imposed by glaucoma in Tanzania, East Africa. An expert panel of eye health professionals was convened to agree current glaucoma practice in Tanzania. In addition a structured patient survey was developed and administered. Supplemental cost and qualit...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 15; no. 6; p. e0232796
Main Authors Murdoch, Ian, Smith, Andrew F, Baker, Helen, Shilio, Bernadetha, Dhalla, Kazim, Peters, Remco PH
Format Journal Article
LanguageEnglish
Published San Francisco Public Library of Science 01.06.2020
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To determine the cost and quality of life impact imposed by glaucoma in Tanzania, East Africa. An expert panel of eye health professionals was convened to agree current glaucoma practice in Tanzania. In addition a structured patient survey was developed and administered. Supplemental cost and quality of life information was collected using cost questionnaires and validated quality of life measures, including the EQ5D and VFQ-25. Key findings include following. Non-adherence is a major issue, especially in rural settings where over 50% of the patients may fail to return for review. Whilst medical therapy is overwhelmingly the first line treatment, the cost of maintaining this represents up to 25% of a patient's income. There is an impact of glaucoma on patients general well-being as determined by the EQ-5D and more tellingly on visual function with particular impact on role limitations as determined by the VF25. Despite our sample being taken in a private clinic and thus containing a much larger proportion of professionals than the general population, one third of the population earned Tanzanian Shillings (TZS) 170,000 per month which is below the minimum wage. These findings are of great importance for health care planners seeking to determine cost-effective, acceptable methods of both identifying and treating this major cause of preventable blindness.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Competing Interests: Author AFS is a consultant to Medmetrics Inc and was a paid health economics consultant on this project. This does not alter our adherence to PLOS ONE policies on sharing data and materials. No other authors have any competing interests to declare.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0232796